Gadobutrol
This gadolinium-based MRI contrast agent has a high concentration formulation that enhances the visibility of tumors and other abnormalities in the brain, spine, and blood vessels. Its high relaxivity and stability make it suitable for a wide range of diagnostic imaging applications.
Moleküler Ağırlık
604,7000 g/mol
TPSA
194,00 Ų
Terapötik Alanlar
Etki Mekanizması
Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.
2D Yapı
Cite this structure
Embed this structure
SMILES
C1CN(CCN(CCN(CCN1CC(=O)[O-])CC(=O)[O-])[C@H](CO)[C@@H](CO)O)CC(=O)[O-].[Gd+3]
InChI
InChI=1S/C18H34N4O9.Gd/c23-12-14(15(25)13-24)22-7-5-20(10-17(28)29)3-1-19(9-16(26)27)2-4-21(6-8-22)11-18(30)31;/h14-15,23-25H,1-13H2,(H,26,27)(H,28,29)(H,30,31);/q;+3/p-3/t14-,15-;/m1./s1
Molecular Formula
C18H31GdN4O9
HBD / HBA
3 / 13
Döndürülebilir Bağlar
7
Ağır Atomlar
32
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
This gadolinium-based MRI contrast agent has a high concentration formulation that enhances the visibility of tumors and other abnormalities in the brain, spine, and blood vessels. Its high relaxivity and stability make it suitable for a wide range of diagnostic imaging applications.
Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.
Yes, Gadobutrol is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2218860. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 6102852. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="gadobutrol"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/gadobutrol/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/gadobutrol/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/gadobutrol/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="gadobutrol"></drugfyi-drug>